Tribunal Decides Transfer Pricing & Tax Disallowance Issues

The Tribunal directed the determination of Arm's Length Price (ALP) for international transactions separately for supply of raw materials and import of products, with the subvention fee set off against any transfer pricing adjustment. The characterization of transactions between the Assessee and Torrent Pharmaceuticals Ltd. was clarified, distinguishing between international transactions and those not resulting in tax base erosion in India. Disallowance under Section 40(a)(ia) was subject to verification of tax payments by TPL. Comparable companies were excluded based on functional dissimilarity, and recharacterization of services as Clinical Trial Services was remanded for further evidence consideration. The appeal was partly allowed, with specific issues remanded for fresh review.

---

---

Issues Involved:
1. Determination of Arm's Length Price (ALP) for international transactions.
2. Characterization of transactions between the Assessee and Torrent Pharmaceuticals Ltd. (TPL).
3. Disallowance under Section 40(a)(ia) of the Income Tax Act, 1961.
4. Inclusion/exclusion of comparable companies for Transfer Pricing analysis.
5. Recharacterization of services provided by the Assessee as Clinical Trial Services.

Detailed Analysis:

1. Determination of Arm's Length Price (ALP) for International Transactions:
The Assessee, a subsidiary of Novo Nordisk A/S, Denmark, engaged in trading high purity insulin formulations and other pharmaceutical products, reported several international transactions with its Associated Enterprises (AE). The Assessee adopted the Transaction Net Margin Method (TNMM) as the Most Appropriate Method (MAM) for determining the ALP of combined transactions termed as the "Distribution Segment." The Transfer Pricing Officer (TPO) recharacterized the transactions as manufacturing activities and applied the Profit Split Method (PSM), resulting in an ALP adjustment of INR 352,638,074, which was further enhanced by INR 58,831,508. The Tribunal, following its decision in AY 09-10, directed that the determination of ALP for supply of raw materials and import of products should be done separately, and the subvention fee received should be set off against any transfer pricing adjustment.

2. Characterization of Transactions Between the Assessee and TPL:
The Tribunal examined the agreements between the Assessee, TPL, and Novo Nordisk A/S, concluding that the arrangement was a concerted action for manufacturing and selling insulin products in India. The Tribunal held that the transaction of supply of excepients by Novo Nordisk A/S to TPL was an international transaction between the Assessee and Novo Nordisk A/S, attracting the provisions of Section 92(1) and 92B(1) of the Act. However, the transaction between TPL and the Assessee for manufacturing insulin vials did not fall within the ambit of Section 92(1) as it did not result in tax base erosion in India.

3. Disallowance Under Section 40(a)(ia):
The AO disallowed the Assessee's claim for deduction of INR 192,89,16,836 paid to TPL for insulin vials, invoking Section 40(a)(ia) for non-deduction of tax at source. The Tribunal, considering the amendment to Section 40(a)(ia) by the Finance Act, 2012, which is retrospective, directed the AO to verify if TPL had included the receipts in its return of income and paid taxes thereon. If verified, the disallowance should be deleted.

4. Inclusion/Exclusion of Comparable Companies:
The Assessee contested the inclusion of Accentia Technology Limited and Infosys BPO Ltd. as comparables for its ITES segment. The Tribunal, following its earlier decisions, directed the exclusion of these companies from the list of comparables, as they were not functionally similar to the Assessee's ITES activities.

5. Recharacterization of Services Provided by the Assessee as Clinical Trial Services:
The TPO recharacterized the Assessee's administrative support services as clinical trial services, leading to an ALP adjustment of INR 1,17,46,336. The Assessee argued that it only provided coordination services for clinical trials conducted by independent investigators. The Tribunal remanded the issue for fresh consideration, directing the Assessee to substantiate its claim with supporting evidence and allowing the AO/TPO to reconsider the comparables chosen.

Conclusion:
The Tribunal provided detailed directions for the determination of ALP, characterization of transactions, and reconsideration of comparables, ensuring that the Assessee's contentions were adequately addressed and verified by the AO/TPO. The appeal was partly allowed, with specific issues remanded for fresh consideration.

---